We’re studying about Medicare drug costs, FDA voucher program
Completely satisfied Thanksgiving Eve, Pharmalittle readers. That is Allison, filling in for Mr. Pharmalot. I lately hosted a mini Thanksgiving dinner for buddies, and was stumped attempting to select music to play within the background. Why aren’t there any actual Thanksgiving songs? We’ve an overabundance of Christmas music. I actually can’t play Adam Sandler’s Thanksgiving tune time and again all evening. Please attain out when you have any music options! This article, and Ed, will likely be again in your inbox Monday morning. Now onto the information. …
The Trump administration on Tuesday night unveiled the costs for 15 medicine that have been the topic of Medicare negotiations for the second 12 months, STAT experiences. The administration stated it saved $8.5 billion, or 36%, in comparison with what it will’ve paid final 12 months had the negotiated costs been in impact. The negotiated-price medicine embody Novo Nordisk’s semaglutide, offered below the manufacturers Ozempic and Rybelsus for diabetes and Wegovy for weight reduction and cardiovascular threat prevention.
Because the U.S. Meals and Drug Administration’s Commissioner’s Nationwide Precedence Voucher program has picked up steam, questions and criticisms in regards to the initiative have been constructing past biopharma, Fierce Biotech particulars. With a letter to Commissioner Marty Makary, Democratic New Jersey Rep. Frank Pallone Jr. and Unbiased Vermont Sen. Bernie Sanders shared “deep considerations” about this system, noting that it has not obtained congressional authorization.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
